Literature DB >> 32474027

NMDA receptors are altered in the substantia nigra pars reticulata and their blockade ameliorates motor deficits in experimental parkinsonism.

Giacomo Sitzia1, Ioannis Mantas2, Xiaoqun Zhang2, Per Svenningsson2, Karima Chergui3.   

Abstract

In Parkinson's disease (PD) reduced levels of dopamine (DA) in the striatum lead to an abnormal circuit activity of the basal ganglia and an increased output through the substantia nigra pars reticulata (SNr) and the globus pallidus internal part. Synaptic inputs to the SNr shape its activity, however, the properties of glutamatergic synaptic transmission in this output nucleus of the basal ganglia in control and DA-depleted conditions are not fully elucidated. Using whole-cell patch-clamp recordings and pharmacological tools, we examined alterations in glutamatergic synaptic transmission in the SNr of a mouse model of PD, i.e. mice with unilateral 6-OHDA lesion of DA neurons in the substantia nigra pars compacta, as compared to control mice. We found that AMPA receptor (AMPAR)-mediated spontaneous and evoked excitatory postsynaptic currents (sEPSCs and eEPSCs) were not altered. The AMPA/NMDA ratio was significantly decreased in 6-OHDA-lesioned mice, suggesting an increased synaptic function of NMDA receptors (NMDARs) in DA-depleted mice. The decay kinetics of NMDAR-eEPSCs were faster in 6-OHDA-lesioned mice, indicating a possible change in the subunit composition of synaptic NMDARs. In control mice NMDAR-eEPSCs were mediated by diheteromeric NMDARs made of GluN2A, GluN2B and GluN2D. In 6-OHDA-lesioned mice the function of diheteromeric NMDARs containing either GluN2B or GluN2D was dramatically decreased, whereas the function of diheteromeric NMDARs made of GluN2A was preserved. Microinjections of an NMDAR antagonist into the SNr of 6-OHDA-lesioned mice resulted in significant improvements in spontaneous locomotion. This study identifies novel alterations occurring at excitatory synapses in the basal ganglia output nucleus following DA depletion. An increased synaptic NMDAR function, due to an altered subunit composition, might contribute to hyperactivation of SNr neurons in the DA depleted state and to motor impairments in PD.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Basal ganglia; GluN2 subunits; NMDA receptors; Parkinson's disease; Substantia nigra reticulata; Synaptic transmission

Mesh:

Substances:

Year:  2020        PMID: 32474027     DOI: 10.1016/j.neuropharm.2020.108136

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  4 in total

Review 1.  Progresses in GluN2A-containing NMDA Receptors and their Selective Regulators.

Authors:  Menghan Niu; Xin Yang; Yuanyuan Li; Yanping Sun; Long Wang; Jing Ha; Yinghua Xie; Zibin Gao; Changzheng Tian; Le Wang; Yongjun Sun
Journal:  Cell Mol Neurobiol       Date:  2022-01-03       Impact factor: 5.046

Review 2.  Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels.

Authors:  Kasper B Hansen; Lonnie P Wollmuth; Derek Bowie; Hiro Furukawa; Frank S Menniti; Alexander I Sobolevsky; Geoffrey T Swanson; Sharon A Swanger; Ingo H Greger; Terunaga Nakagawa; Chris J McBain; Vasanthi Jayaraman; Chian-Ming Low; Mark L Dell'Acqua; Jeffrey S Diamond; Chad R Camp; Riley E Perszyk; Hongjie Yuan; Stephen F Traynelis
Journal:  Pharmacol Rev       Date:  2021-10       Impact factor: 18.923

3.  LRRK2-G2019S mice display alterations in glutamatergic synaptic transmission in midbrain dopamine neurons.

Authors:  Olga Skiteva; Ning Yao; Giacomo Sitzia; Karima Chergui
Journal:  J Neurochem       Date:  2022-02-27       Impact factor: 5.546

4.  High-Frequency Deep Brain Stimulation of the Substantia Nigra Pars Reticulata Facilitates Extinction and Prevents Reinstatement of Methamphetamine-Induced Conditioned Place Preference.

Authors:  Libo Zhang; Shiqiu Meng; Wenjun Chen; Yun Chen; Enze Huang; Guipeng Zhang; Yisen Liang; Zengbo Ding; Yanxue Xue; Yun Chen; Jie Shi; Yu Shi
Journal:  Front Pharmacol       Date:  2021-06-30       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.